Genes encoding SWI/SNF chromatin remodeling complex subunits are collectively mutated
in approximately 20% of human cancers. ARID1A is a SWI/SNF subunit gene whose protein …

Abstract Development of novel strategies to overcome chemoresistance is central goal in
ovarian cancer research. Natural history of the cancer development and progression is …

In ovarian cancer patients, tumor fibrosis and angiotensin-driven fibrogenic signaling have
been shown to inversely correlate with survival. We sought to enhance drug delivery and …

Low‐grade serous ovarian carcinoma (LGSOC) is associated with a poor response to
existing chemotherapy, highlighting the need to perform comprehensive genomic analysis …

Despite the promise of ribonucleic acid interference therapeutics, the delivery of
oligonucleotides selectively to diseased tissues in the body, and specifically to the cellular …

Purpose: PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast
and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other …

Ovarian cancer is a common and complex malignancy with poor prognostic outcome. Most
women with ovarian cancer are diagnosed with advanced stage disease due to a lack of …

Background ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in
patients with previously treated locally advanced/unresectable or metastatic urothelial …

Objective This meta-analysis investigated the effectiveness of PARP inhibitors (PARPis) as
maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC), stratifying …

Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the
world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is …